Relationships between nutrition, alcohol use, and liver disease

Charles S Lieber, Charles S Lieber

Abstract

Many alcoholics are malnourished, either because they ingest too little of essential nutrients (e.g., carbohydrates, proteins, and vitamins) or because alcohol and its metabolism prevent the body from properly absorbing, digesting, and using those nutrients. As a result, alcoholics frequently experience deficiencies in proteins and vitamins, particularly vitamin A, which may contribute to liver disease and other serious alcohol-related disorders. Furthermore, alcohol breakdown in the liver, both by the enzyme alcohol dehydrogenase and by an enzyme system called the microsomal ethanol-oxidizing system (MEOS), generates toxic products such as acetaldehyde and highly reactive, and potentially damaging, oxygen-containing molecules. These products can interfere with the normal metabolism of other nutrients, particularly lipids, and contribute to liver cell damage. Nutritional approaches can help prevent or ameliorate alcoholic liver disease. For example, a complete balanced diet can compensate for general malnutrition. Administration of antioxidants (e.g., precursors of the endogenous antioxidant glutathione) can help the body eliminate reactive oxygen molecules and other reactive molecules generated from abnormal lipid breakdown. New agents currently are being studied as promising nutritional supplements for alcoholics with liver disease.

Figures

Figure 1
Figure 1
Interaction of alcohol’s direct toxic effects with malnutrition. In alcoholics, alcohol often replaces other nutrients (e.g., carbohydrates or proteins), resulting in insufficient intake of those nutrients (i.e., primary malnutrition), particularly because, under certain conditions, the calories provided by alcohol cannot be used effectively by the body—that is, they are “empty” calories. In addition, alcohol has direct toxic effects on the gastrointestinal tract and liver, leading to impaired digestion, reduced absorption of nutrients into the blood, and impaired utilization or increased degradation of those nutrients. These effects are referred to as secondary malnutrition and can contribute to the progression of liver damage. SOURCE: Lieber 1991b.
Figure 2
Figure 2
Vitamin A levels in the livers of healthy people and patients with various stages of alcoholic liver disease. The values were obtained by taking liver biopsies from study participants. Each circle or x represents one person; a filled circle represents a living participant, an open circle represents a sample taken during an autopsy of a deceased participant, and each x represents a study participant with a normal liver who had diabetes. The bars represent the mean value of all participants in each group. P values for the differences between the groups were all significant at the 0.001 level. SOURCE: Leo and Lieber 1982.
Figure 3
Figure 3
Effects of heavy alcohol consumption caused by alcohol-related malnutrition and alcohol breakdown by the enzyme alcohol dehydrogenase (ADH) and the microsomal ethanol-oxidizing system (MEOS). Alcohol consumption can lead to primary and secondary malnutrition as described in figure 1. Alcohol breakdown by ADH results in the formation of excess levels of the molecule reduced nicotinamide adenine dinucleotide (NADH), which can cause various metabolic problems. Moreover, both ADH and the MEOS convert alcohol to acetaldehyde, a toxic molecule that has numerous adverse effects. Alcohol also enhances the activity of the central enzyme of the MEOS, cytochrome P450 2E1, which exacerbates some of the toxic effects of acetaldehyde and generates a harmful condition called oxidative stress in the cells. Oxidative stress is characterized by excess levels of reactive oxygen species (ROS), abnormal lipid breakdown resulting in additional reactive molecules, and/or reduced levels of antioxidants (e.g., glutathione) which can eliminate reactive molecules. SOURCE: Modified from Lieber 1998.
Figure 4
Figure 4
Alcohol’s effects on the levels of reactive molecules and the antioxidant glutathione (GSH) in the cell. (A) Alcohol breakdown by the enzyme alcohol dehydrogenase (ADH) and by the microsomal ethanol-oxidizing system (MEOS) generates acetaldehyde, a reactive molecule that among other harmful effects interacts with cysteine, preventing it from being used to generate GSH (see panel B). Both the MEOS and acetaldehyde also lead to the generation of reactive oxygen species (ROS) that damage the cells through various mechanisms (e.g., lipid peroxidation). ROS can be eliminated or converted to harmless substances by GSH and other antioxidants. (B) One of the precursors of GSH is the amino acid methionine, which first is converted to S-adenosylmethionine (SAMe). SAMe then is further modified to yield cysteine. Alcohol consumption and alcoholic liver disease cause the blocks labeled a and b; both folate and vitamin B12 deficiency cause block c; vitamin B6 deficiency causes block d; and all these blockages interfere with GSH production. Administration of SAMe can help raise GSH levels in the cells.

References

    1. Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P–4502E1, 1A2 and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcoholism: Clinical and Experimental Research. 1998;22:2125–2132.
    1. Tsutsumi M, Lasker JM, Shimizu M, et al. The intralobular distribution of ethanol inducible P450IIE1 in rat and human liver. Hepatology. 1989;10:437–446.
    1. Adibi SA, Baraona E, Lieber CS. Effects of ethanol on amino acids and protein metabolism. In: Lieber CS, editor. Medical and Nutritional Complications of Alcoholism: Mechanism and Management. New York: Plenum Press; 1992. pp. 127–155.
    1. Ahmed S, Leo MA, Lieber CS. Interactions between alcohol and beta-carotene in patients with alcoholic liver disease. American Journal of Clinical Nutrition. 1994;60:430–436.
    1. Albanes D, Heinonen OP, Taylor PR, et al. α-tocopherol and β-carotene supplements and lung cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study: Effects of baseline characteristics and study compliance. Journal of the National Cancer Institute. 1996;88:1560–1571.
    1. Aleynik SI, Leo MA, Aleynik MK, Lieber CS. Polyenylphosphatidylcholine prevents carbontetrachloride-induced lipid peroxidation while it attenuates liver injury and fibrosis. Journal of Hepatology. 1997;26:554–561.
    1. Alpha-Tocopherol Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine. 1994;330:1029–1035.
    1. Bode JL, Buchwald B, Goebell H. Inhibition of ethanol breakdown due to protein deficiency in man. German Medical Monthly. 1971;1:149–151.
    1. Casini A, Cunningham M, Rojkind M, Lieber CS. Acetaldehyde increases procollagen type I and fibronectin gene transcription in cultured rat fat-storing cells through a protein synthesis-dependent mechanism. Hepatology. 1991;13:758–765.
    1. Chedid A, Mendenhall CL, Gartside P, et al. Prognostic factors in alcoholic liver disease. American Journal of Gastroenterology. 1991;82:210–216.
    1. de la Maza MP, Petermann M, Bunout D, Hirsch S. Effects of long-term vitamin E supplementation in alcoholic cirrhotics. Journal of the American College of Nutrition. 1995;14:192–196.
    1. Feinman L, Lieber CS. Nutrition and diet in alcoholism. In: Shils ME, Olson JA, Shike M, Ross AC, editors. Modern Nutrition in Health and Disease. 9th ed. Baltimore: Williams & Wilkins; 1998. pp. 1523–1542.
    1. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. Journal of Hepatology. 1989;9:105–113.
    1. Gruchow HW, Sobociaski KA, Barboriak JJ. Alcohol nutrient intake and hypertension in U.S. adults. JAMA: Journal of the American Medical Association. 1985;253:1567–1570.
    1. Koop DR, Casazza JP. Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. Journal of Biological Chemistry. 1985;260:13607–13612.
    1. Leo MA, Lieber CS. Hepatic vitamin A depletion in alcoholic liver injury. New England Journal of Medicine. 1982;307:597–601.
    1. Leo MA, Lieber CS. Hepatic fibrosis after long-term administration of ethanol and moderate vitamin A supplementation in the rat. Hepatology. 1983;3:1–11.
    1. Leo MA, Lieber CS. Alcohol, vitamin A, and beta-carotene: Adverse interactions, including hepatotoxicity and carcinogenicity. American Journal of Clinical Nutrition. 1999;69:1071–1085.
    1. Leo MA, Arai M, Sato M, Lieber CS. Hepatotoxicity of vitamin A and ethanol in the rat. Gastroenterology. 1982;82:194–205.
    1. Leo MA, Sato M, Lieber CS. Effect of hepatic vitamin A depletion on the liver in humans and rats. Gastroenterology. 1983;84:562–572.
    1. Leo MA, Kim C, Lieber CS. Increased vitamin A in esophagus and other extrahepatic tissues after chronic ethanol consumption in the rat. Alcoholism: Clinical and Experimental Research. 1986;10:487–492.
    1. Leo MA, Lowe N, Lieber CS. Potentiation of ethanol-induced hepatic vitamin A depletion by phenobarbital and butylated hydroxytoluene. Journal of Nutrition. 1987;117:70–76.
    1. Leo MA, Kim CI, Lowe N, Lieber CS. Interaction of ethanol with ß-carotene: Delayed blood clearance and enhanced hepatotoxicity. Hepatology. 1992;15:883–891.
    1. Leo MA, Rosman A, Lieber CS. Differential depletion of carotenoids and tocopherol in liver diseases. Hepatology. 1993;17:977–986.
    1. Lieber CS. Alcohol and the liver. In: Arai IM, Frenkel MS, Wilson JHP, editors. Liver Annual VI. Amsterdam: Excerpta Medica; 1987. pp. 163–240.
    1. Lieber CS. Perspectives: Do alcohol calories count? American Journal of Clinical Nutrition. 1991a;54:976–982.
    1. Lieber CS. Hepatic, metabolic and toxic effects of ethanol: 1991 update. Alcoholism: Clinical and Experimental Research. 1991b;15:573–592.
    1. Lieber CS. Medical and Nutritional Complications of Alcoholism: Mechanisms and Management. New York: Plenum Press; 1992.
    1. Lieber CS. Cytochrome P-4502E1: Its physiological and pathological role. Physiological Reviews. 1997;77:517–544.
    1. Lieber CS. Hepatic and other medical disorders of alcoholism: From pathogenesis to treatment. Journal of Studies on Alcohol. 1998;59:9–25.
    1. Lieber CS. Alcohol: Its metabolism and interaction with nutrients. Annual Review of Nutrition. 2000;20:395–430.
    1. Lieber CS. S-adenosylmethionine (SAMe): Its role in the treatment of liver disorders. American Journal of Clinical Nutrition. 2002;76:1183S–1187S.
    1. Lieber CS, DeCarli LM. Quantitative relationship between the amount of dietary fat and the severity of the alcoholic fatty liver. American Journal of Clinical Nutrition. 1970;23:474–478.
    1. Lieber CS, Schmid R. The effect of ethanol on fatty acid metabolism: Stimulation of hepatic fatty acid synthesis in vitro. Journal of Clinical Investigation. 1961;40:394–399.
    1. Lieber CS, Lefevre A, Spritz N, et al. Difference in hepatic metabolism of long and medium-chain fatty acids: The role of fatty acid chain length in the production of the alcoholic fatty liver. Journal of Clinical Investigation. 1967;46:1451–1460.
    1. Lieber CS, Casini A, DeCarli LM, et al. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology. 1990;11:165–172.
    1. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology. 1994;106:152–159.
    1. Lieber CS, Leo MA, Aleynik SI, et al. Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcoholism: Clinical and Experimental Research. 1997;21:375–379.
    1. Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. Journal of Clinical Gastroenterology. 2003;37:336–339.
    1. Ma X, Zhao J, Lieber CS. Polyenylphosphatidylcholine attenuates nonalcoholic hepatic fibrosis and accelerates its regression. Journal of Hepatology. 1996;24:604–613.
    1. Martin-Duce AM, Ortiz P, Cabrero C, Mato JM. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis. Hepatology. 1988;8:65–68.
    1. Mato JM, Camara J, Fernandez de Paz J, et al. S-adenosylmethionine in alcoholic liver cirrhosis: A randomized placebo-controlled double-blind multicenter clinical trial. Journal of Hepatology. 1999;30:1081–1089.
    1. Mendenhall C, Roselle GA, Gartside P, et al. Relationship of protein calorie malnutrition to alcoholic liver disease: A reexamination of data from two Veterans Administration Cooperative studies. Alcoholism: Clinical and Experimental Research. 1995;19:635–641.
    1. Nanji AA, Yang EK, Fogt F, et al. Medium-chain triglycerides and vitamin E reduce the severity of established experimental alcoholic liver disease. Journal of Pharmacology and Experimental Therapeutics. 1996;277:1694–1700.
    1. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled double-blind randomized and multicenter trial. Journal of Hepatology. 1998;28:615–621.
    1. Pirola RC, Lieber CS. The energy cost of the metabolism of drugs including ethanol. Pharmacology. 1972;7:185–196.
    1. Sato M, Lieber CS. Hepatic vitamin A depletion after chronic ethanol consumption in baboons and rats. Journal of Nutrition. 1981;111:2015–2023.
    1. Shaw S, Rubin KP, Lieber CS. Depressed hepatic glutathione and increased diene conjugates in alcoholic liver disease: Evidence of lipid peroxidation. Digestive Diseases and Sciences. 1983;28:585–589.
    1. Tsutsumi M, Lasker JM, Shimizu M, et al. The intralobular distribution of ethanol inducible P450IIE1 in rat and human liver. Hepatology. 1989;10:437–446.

Source: PubMed

3
Předplatit